4D Molecular Therapeutics acquires eye disease asset from Fortress Biotech subsidiary

Tyler Patchen

News Reporter

California-based biotech 4D Molecular Therapeutics (4DMT) will be acquiring the rights to an asset from a company under the Fortress Biotech umbrella.

On Monday, 4DMT …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

4D Molecular Therapeutics acquires eye disease asset from Fortress Biotech subsidiary

Tyler Patchen

News Reporter

Sign up to read this article for free.

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Novo Nordisk CEO to step down, timeline for successor unknown

'Go ahead and do it': Top RFK Jr. deputy dares drugmakers that might pull manufacturing over new price pressure

Novo Nordisk’s global obesity leader is moving on; Flagship biotech gets CEO from Scholar Rock

The inside story of the six-month sprint to create the first custom CRISPR therapy for one infant’s rare disease

It's been three months without a biotech IPO

RFK Jr. adopts new chikungunya vaccine guidance; other recommendations remain under review

4D Mol­e­c­u­lar Ther­a­peu­tics ac­quires eye dis­ease as­set from Fortress Biotech sub­sidiary

News Reporter

Sign up to read this article for free.

more like this

Autonomy Bio Inc.

San Francisco, CA 94107, USA

4D Molecular Therapeutics acquires eye disease asset from Fortress Biotech subsidiary